Tipiracil
In clinical developmentAlso known as Lonsurf, Tipiracilo, 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione.
Recent clinical, regulatory, research and industry developments relating to this drug.
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes3
Journals, researchers & institutions
- The New England journal of medicine1
- Amellal N1
- Benhadji KA1
- Bondarenko I1
- Ciardiello F1
- Cremolini C1
- Cruz FM1
- Elez E1
- Fakih M1
- Comprehensive Cancer Center1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 3 of the same disease areas as Tipiracil in the shared literature.
Studied across 3 of the same disease areas as Tipiracil in the shared literature.
Studied across 3 of the same disease areas as Tipiracil in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials